Evidence map›Paper›PMID 41366016›Full record

ArticleScientific reports2025

Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models.

Sikun Meng, Tomoaki Hara, Tetsuya Sato, Shotaro Tatekawa, Yasuko Arao, Yoshiko Saito, Toshiro Hirai, Daisuke Motooka, Sarah Rennie, Taroh Satoh and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. New approach methodologies (NAMs) for preclinical and translational evaluation of mRNA-lipid nanoparticle (LNP) therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Sikun MengDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Tomoaki HaraDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Tetsuya SatoBiomedical Research Center, Faculty of Medicine, Saitama Medical University, 1397-1 Yamane, Hidaka, Saitama, 350-1241, Japan.
Shotaro TatekawaDepartment of Radiation Oncology, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Yasuko AraoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Yoshiko SaitoDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Toshiro HiraiVaccine Creation Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, The University of Osaka, Yamadaoka 2-1, Suita, Osaka, 565-0871, Japan.
Daisuke MotookaResearch Institute for Microbial Diseases, The University of Osaka, Yamadaoka 3-1, Suita, Osaka, 565-0871, Japan.
Sarah RennieSection for Computational and RNA Biology, Department of Biology, University of Copenhagen, DK2200 Copenhagen N, Copenhagen, Denmark.
Taroh SatohDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Kazuhiko OgawaDepartment of Radiation Oncology, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Yutaka MiuraLaboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, 4259 Nagatsutacho, Midori-ku, Yokohama, Kanagawa, 226-8501, Japan.
Masaki MoriTokai University Graduate School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Yuichiro DokiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Hidetoshi EguchiDepartment of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan.
Hideshi IshiiDepartment of Medical Data Science, Center of Medical Innovation and Translational Research, Graduate School of Medicine, The University of Osaka, Yamadaoka 2-2, Suita, Osaka, 565-0871, Japan. hishii@gesurg.med.osaka-u.ac.jp.

Funding

Institute for Fermentation, Osaka G2024-3-006Japan Agency for Medical Research and Development JP23ym0126809, JP24ym0126809Ministry of Education, Culture, Sports, Science and Technology 23K18313, 24K02518, 23KK0153, 24K22144, 23K19505, 24K19992, 25H01060Suzuken Memorial Foundation 2024Uehara Memorial Foundation 2024
6 · The paper itself

Abstract

The therapeutic potential of chimeric antigen receptor (CAR) T-cell therapy in treating solid tumors is highly recognized, yet the complex and immunosuppressive nature of the tumor microenvironment, poor accessibility, and the instability of target antigens pose substantial challenges. Here, we present an mRNA-LNP-based therapeutic strategy that delivers mRNA encoding a fibroblast activation protein (FAP)-specific CAR to reprogram host immune cells in vivo and target cancer-associated fibroblasts within the tumor stroma. In multiple solid tumor mouse models, this approach, combined with chemotherapeutic agents and immune checkpoint inhibitors, achieved significant tumor regression and induced durable, antigen-specific immune memory. Incorporation of m

Indexed as

Fibroblast Activation Protein AlphaImmunotherapy, AdoptiveNanoparticle Drug Delivery SystemNeoplasmsReceptors, Chimeric AntigenAnimalsAntineoplastic Combined Chemotherapy ProtocolsCancer-Associated FibroblastsCell Line, TumorCombined Modality TherapyFemaleGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsKaplan-Meier EstimateLiposomesFAP protein, humanFibroblast Activation Protein AlphaImmune Checkpoint InhibitorsLipid NanoparticlesLiposomesNanoparticle Drug Delivery SystemReceptors, Chimeric AntigenRNA, MessengerCAR-T therapyFibroblast activation proteinmRNASolid tumorTumor microenvironment

Identifiers

PMID41366016
PMCPMC12800119

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.